Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT05800587
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 950
- Registration Number
- NCT05800015
- Locations
- 🇺🇸
Crosson Cancer Institute, Fullerton, California, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05791097
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT05789082
- Locations
- 🇺🇸
MD Anderson Cancer Center; Oncology, Houston, Texas, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT05775289
- Locations
- 🇲🇽
ONCARE Viaducto Napoles, Ciudad de México, Mexico CITY (federal District), Mexico
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain
🇦🇺Monash Health, Clayton, Victoria, Australia
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT05766800
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT05756972
- Locations
- 🇨🇳
Medical Ethics Committee of Guangdong Provincial People's Hospital, Guangzhou, Guangdonng, China
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05751187
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Liza Villaruz, MD
- Target Recruit Count
- 3
- Registration Number
- NCT05746481
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 84
- Registration Number
- NCT05741021
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.